Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews

No studies found 1 · 14.3%GRADE not reported 0 · 0%Very low 2 · 28.6%Low 4 · 57.1%Moderate 0 · 0%High 0 · 0%

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Change in disability score · children and adults with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
19 participants
Very low

Muscle strength · children and adults with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
19 participants
Low

Acquiring the ability to stand or walk · children and adults with SMA types II and III

The review found no eligible studies for this question.

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Change in quality of life · children and adults with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
19 participants
Very low

Change in pulmonary function · children and adults with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
19 participants
Low

Time from beginning of treatment until death or full‐time ventilation · children and adults with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
19 participants
Low

Adverse events related to treatment · children and adults with SMA types II and III

Subcutaneous somatotropin showed no clear difference in adverse events related to treatment compared with placebo (low certainty).

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
RR 1.57 [0.78, 3.17]
19 participants
Low